

Title (en)
APPARATUS AND SYSTEM HAVING DRY GENE SILENCING COMPOSITIONS

Title (de)
VORRICHTUNG UND SYSTEM MIT TROCKENEN KONTROLLGEN-VERSTÜMMUNGSSZUSAMMENSETZUNGEN

Title (fr)
APPAREIL ET SYSTÈME COMPRENANT DES COMPOSITIONS SÈCHES D'EXTINCTION GÉNIQUE

Publication
EP 1814994 A4 20100714 (EN)

Application
EP 05857003 A 20051121

Priority

- US 2005042404 W 20051121
- US 63032004 P 20041122
- US 67816505 P 20050504
- US 28348105 A 20051118
- US 28348205 A 20051118
- US 28348305 A 20051118
- US 28348405 A 20051118

Abstract (en)
[origin: CA2587786A1] A reverse transfection apparatus can be used for introducing siRNA into a cell to effect gene silencing. Such an apparatus can include a well plate having a well configured for transfecting cells. The well can include a substantially dry gene silencing composition that has at least a first siRNA which silences a first target gene. The gene silencing composition can be configured such that the at least first siRNA is capable of being solubilized or suspended in an aqueous medium in an amount sufficient for transfecting cells in the well. Additionally, the at least first siRNA can include a modification or a conjugate. The reverse transfection apparatus can be provided as a kit or system that additionally includes cells, polynucleotide carriers, reverse transfection reagents, and the like.

IPC 8 full level
C12N 15/63 (2006.01); **C07H 21/02** (2006.01); **C07H 21/04** (2006.01); **C12N 15/00** (2006.01); **C12N 15/85** (2006.01); **C12N 15/87** (2006.01); **C12Q 1/68** (2006.01)

CPC (source: EP KR)
C12M 1/00 (2013.01 - KR); **C12M 1/18** (2013.01 - KR); **C12M 1/26** (2013.01 - KR); **C12Q 1/6809** (2013.01 - EP); **G01N 33/502** (2013.01 - EP)

Citation (search report)

- [Y] WO 2004090105 A2 20041021 - DHARMA CON INC [US], et al
- [X] US 2004137064 A1 20040715 - LEWIS DAVID L [US], et al
- [AP] WO 2005097992 A2 20051020 - DHARMA CON INC [US], et al
- [XYI] MINAKUCHI YOSHIKO ET AL.: "Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo", NUCLEIC ACIDS RESEARCH, vol. 32, no. 13, 22 July 2004 (2004-07-22), pages E109.1 - E109.7, XP002513223, ISSN: 1362-4962
- [A] HONMA KIMI ET AL.: "Atelocollagen-based gene transfer in cells allows high-throughput screening of gene functions", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 289, no. 5, 21 December 2001 (2001-12-21), pages 1075 - 1081, XP002957375, ISSN: 0006-291X
- [AP] HONMA K. ET AL.: "The role of atelocollagen-based cell transfection array in high-throughput screening of gene functions and in drug discovery", CURRENT DRUG DISCOVERY TECHNOLOGIES, vol. 1, no. 4, 1 December 2004 (2004-12-01), pages 287 - 294, XP008092990, ISSN: 1570-1638
- See references of WO 2006071410A2

Citation (examination)
AZA-BLANC P ET AL: "Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 12, no. 3, 1 September 2003 (2003-09-01), pages 627 - 637, XP002350184, ISSN: 1097-2765, DOI: 10.1016/S1097-2765(03)00348-4

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
AT E519772 T1 20110815; AU 2005322468 A1 20060706; AU 2005322468 A2 20060706; AU 2005322468 B2 20110310; CA 2587786 A1 20060706; CA 2587786 C 20171205; CN 101107352 A 20080116; CN 101107352 B 20130320; EP 1814895 A2 20070808; EP 1814895 A4 20080528; EP 1814895 B1 20110810; EP 1814994 A2 20070808; EP 1814994 A4 20100714; EP 1815022 A2 20070808; EP 1815022 A4 20090325; JP 2008532480 A 20080821; KR 101277646 B1 20130625; KR 20070118585 A 20071217

DOCDB simple family (application)
AT 05852038 T 20051121; AU 2005322468 A 20051121; CA 2587786 A 20051121; CN 200580047054 A 20051121; EP 05849672 A 20051121; EP 05852038 A 20051121; EP 05857003 A 20051121; JP 2007543423 A 20051121; KR 20077013989 A 20051121